Company: LGNZZ
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000886163-25-000012
Chunk: 133

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-02-28
Form: 10-K
Item: Item 8
Chunk 133
---
22)$2.94 $(1.98)Shares used in diluted per share calculation18,290 17,757 16,868 

See accompanying notes to these consolidated financial statements.

61

LIGAND PHARMACEUTICALS INCORPORATED

 CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(in thousands)

Year Ended December 31, 202420232022Net income (loss)$(4,032)$52,154 $(33,361)Unrealized net gain (loss) on available-for-sale securities, net of tax45 167 (67)Foreign currency translation adjustment, net of tax(5,170)— — Comprehensive income (loss)$(9,157)$52,321 $(33,428)

See accompanying notes to these consolidated financial statements.

62

LIGAND PHARMACEUTICALS INCORPORATED

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY 

(in thousands)Common StockAdditionalpaid-incapitalAccumulatedothercomprehensiveincome (loss)Retain earningsTotalstockholders’equitySharesAmountBalance at December 31, 202116,767 $17 $372,969 $(917)$449,090 $821,159 ASU 2020-06 adoption, net of tax— — (51,130)— 35,133 (15,997)Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes184 — (5,004)— — (5,004)Share-based compensation— — 60,285 — — 60,285 Unrealized net loss on available-for-sale securities, net of tax— — — (67)— (67)Bond hedge transaction— — 202 — — 202 OmniAb Distribution— — (229,732)— — (229,732)Net loss— — — — (33,361)(33,361)Balance at December 31, 202216,951 17 147,590 (984)450,862 597,485 Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes605 1 17,901 — — 17,902 Share-based compensation— — 25,743 —